Heart rate slowing by If current inhibition

著者

書誌事項

Heart rate slowing by If current inhibition

volume editors, A. John Camm, Michal Tendera

（Advances in cardiology, v. 43）

Karger, c2006

  • :hard cover

大学図書館所蔵 件 / 全1件

この図書・雑誌をさがす

注記

Includes bibliographical references and indexes

収録内容

  • Heart rate: a risk factor for cardiac diseases and outcomes? Pathophysiology of cardiac diseases and the potential role of heart rate slowing / Lanza, G.A., Fox, K., Crea, F.
  • If current inhibition: cellular basis and physiology / Mangoni, M.E., Marger, L., Nargeot, J.
  • Heart rate reduction by pharmacological If current inhibition / Cargnoni, A. ... [et al.]
  • Clinical perspectives of heart rate slowing for coronary event reduction and heart failure / Danchin, N., Kadri, Z.
  • Clinical effect of 'pure' heart rate slowing with a prototype If current inhibitor: placebo-controlled experience with ivabradine / Borer, J.S.
  • Heart rate slowing versus other pharmacological antianginal strategies. Results of comparative studies / Diaz, A., Tardif, J.-C.
  • Novel If current inhibitor ivabradine: safety considerations / Savelieva, I., Camm, A.J.
  • Heart rate slowing for myocardial dysfunction/heart failure. Rationale and preclinical studies / Mulder, P., Thuillez, C.
  • Future directions: what data do we need? / Tendera, M

内容説明・目次

内容説明

This book unfolds the history of the discovery of the transmembrane channel which is responsible for the 'funny' or If current, the primary modulator of heart rate. Inhibition of this current leads to slowing of the heart rate, which is an important component of the successful management of angina pectoris. Recently, Ivabradine, a specific and selective inhibitor of the If current, has been developed as an antianginal agent which has been shown to be at least as effective as both beta-blockers and calcium channel blockers for the treatment of angina. The development, efficacy and complications of this therapy are discussed in detail in this book. Furthermore, the clinical benefits from heart rate reduction in patients with coronary artery disease and heart failure and in patients after myocardial infarction are examined. Whether a lower heart rate per se will prolong life is not yet known, but it may offer a new and important life-saving strategy. The current data presented in this volume will be appreciated by cardiologists and general physicians interested in the modern management of angina pectoris and by electrophysiologists and physiologists who would like to understand the importance of heart rate and its regulation.

目次

  • Foreword
  • Heart Rate: A Risk Factor for Cardiac Diseases and Outcomes? Pathophysiology of Cardiac Diseases and the Potential Role of Heart Rate Slowing: Lanza, G.A.
  • Fox, K.
  • Crea, F.
  • If Current Inhibition: Cellular Basis and Physiology: Mangoni, M.E.
  • Marger, L.
  • Nargeot, J.
  • Heart Rate Reduction by Pharmacological If Current Inhibition: Cargnoni, A.
  • Ceconi, C.
  • Stavroula, G.
  • Ferrari, R.
  • Clinical Perspectives of Heart Rate Slowing for Coronary Event Reduction and Heart Failure: Danchin, N.
  • Kadri, Z.
  • Clinical Effect of 'Pure' Heart Rate Slowing with a Prototype If Current Inhibitor: Placebo-Controlled Experience with Ivabradine: Borer, J.S.
  • Heart Rate Slowing versus Other Pharmacological Antianginal Strategies. Results of Comparative Studies: Diaz, A.
  • Tardif, J.-C.
  • Novel If Current Inhibitor Ivabradine: Safety Considerations: Savelieva, I.
  • Camm, A.J.
  • Heart Rate Slowing for Myocardial Dysfunction/Heart Failure. Rationale and Preclinical Studies: Mulder, P.
  • Thuillez, C.
  • Future Directions: What Data Do We Need? Tendera, M.
  • Author Index
  • Subject Index.

「Nielsen BookData」 より

関連文献： 1件中  1-1を表示

詳細情報

ページトップへ